© COPYRIGHT 2023 IMAGEN THERAPEUTICS LTD.
Company Registered in England & Wales No. 06373341
New treatment strategies are urgently needed for metastatic breast cancer, which remains an area of high unmet need with poor prognosis for patients and a low 5-year survival rate after initial diagnosis. New drugs have historically been developed using cell lines been grown on plastic surfaces for decades. Data obtained from this type of models have led to poor translatability to patients and high attrition rates in oncology drug development.
More advanced patient-derived models have increasingly been adopted as more patient-relevant models for drug screening.
© COPYRIGHT 2023 IMAGEN THERAPEUTICS LTD.
Company Registered in England & Wales No. 06373341